Patients newly diagnosed with PAH are often undertreated relative to treatment recommendations outlined in current guidelines.

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses ...

The main pulmonary artery diameter, esophageal dilatation, and ILD score are independent risk factors for 5-year all-cause mortality in patients with connective tissue disease-associated PAH.

SAN ANTONIO — Patients given higher doses of oral and subcutaneous treprostinil experience a significantly longer time before their first pulmonary arterial hypertension (PAH)-related and all-cause ...

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) prevalence is higher among Medicaid beneficiaries, with significant racial and ethnic disparities, particularly affecting Black ...

Learn how to prepare for cold and flu season with pulmonary hypertension, including prevention steps and early warning signs.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Yutrepia, an inhaled dry powder formulation of treprostinil, has been prescribed to more than 2,800 patients since its approval last year.

KIDS. I WAS PLAYING BASKETBALL AND I WAS BICYCLING AND DOING ALL THE THINGS I WANTED TO DO WHEN SUDDENLY I COULDN’T. DIAGNOSED WITH PULMONARY ARTERIAL HYPERTENSION OR PAH MIKE BENNETT LEARNED HE WAS ...

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...